Genetic Variations in TGFβ1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Non–Small-Cell Lung Cancer Shuanghu (Tiger) Yuan,

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk Ping Yang, MD,

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non–Small Cell Lung Cancer Christina K. Speirs, MD, PhD, Todd.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Lower Incidence of Esophagitis in the Elderly Undergoing Definitive Radiation Therapy for Lung Cancer Payal D. Soni, MD, Philip S. Boonstra, PhD, Matthew.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

Semiquantification and Classification of Local Pulmonary Function by V/Q Single Photon Emission Computed Tomography in Patients with Non-small Cell Lung.

Prognostic Factors in Completely Resected Node-Negative Lung Adenocarcinoma of 3 cm or Smaller Jung-Jyh Hung, MD, PhD, Yi-Chen Yeh, MD, Yu-Chung Wu,

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

Detection of Lung Cancer by Automated Sputum Cytometry

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Yang Zhang, MD, Haiquan Chen, MD, PhD

“The Best-Laid Plans … Often go Awry …”

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Erratum Journal of Thoracic Oncology

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

ERCC2/XPD Polymorphisms and Lung Cancer Risk

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Marginal pulmonary function should not preclude lobectomy in selected patients with non–small cell lung cancer Matthew D. Taylor, MD, Damien J. LaPar,

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Combined Analysis of V20, VS5, Pulmonary Fibrosis Score on Baseline Computed Tomography, and Patient Age Improves Prediction of Severe Radiation Pneumonitis.

A Phase II Study of Irinotecan and Carboplatin in Advanced Non-small Cell Lung Cancer with Pharmacogenomic Analysis: Final Report Giancarlo A. Pillot,

Genetic Changes in Squamous Cell Lung Cancer: A Review

Systematic Evaluation of Genetic Variants in Three Biological Pathways on Patient Survival in Low-Stage Non-small Cell Lung Cancer V. Shane Pankratz,

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

The Effects of Increased Provision of Thoracic Surgical Specialists on the Variation in Lung Cancer Resection Rate in England Kelvin K.W. Lau, DPhil,

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Robert J. Cerfolio, MD, FACS, FCCP, Ayesha S. Bryant, MSPH, MD

Annemarie Becker, MD, PhD, Atie van Wijk, RN, Egbert F

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

A Review of First-Line Treatment for Small-cell Lung Cancer

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Genetic Variations in TGFβ1, tPA, and ACE and Radiation-Induced Thoracic Toxicities in Patients with Non–Small-Cell Lung Cancer Shuanghu (Tiger) Yuan, MD, PhD, Vicki L. Ellingrod, PharmD, BCPP, FCCP, Matthew Schipper, PhD, Kathleen A. Stringer, PharmD, Xuwei Cai, MD, PhD, James A. Hayman, MD, Jinming Yu, MD, PhD, Theodore S. Lawrence, MD, PhD, Feng-Ming (Spring) Kong, MD, PhD Journal of Thoracic Oncology Volume 8, Issue 2, Pages 208-213 (February 2013) DOI: 10.1097/JTO.0b013e318274592e Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 The incidence of radiation-induced thoracic toxicity. Toxicity grade was determined prospectively per Common Terminology Criteria for Adverse Events 3.0 standard. Journal of Thoracic Oncology 2013 8, 208-213DOI: (10.1097/JTO.0b013e318274592e) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Genotypes and radiation-induced thoracic toxicity. Toxicity grade was determined prospectively per Common Terminology Criteria for Adverse Events 3.0 standard. TGFβ1, transforming growth factor–beta1; ACE, angiotensin-converting enzyme; tPA, tissue plasminogen activator; RITT, combined radiation-induced thoracic toxicity. Journal of Thoracic Oncology 2013 8, 208-213DOI: (10.1097/JTO.0b013e318274592e) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Radiation thoracic toxicity and sensitive genotypes in TGFβ1 pathway. Toxicity grade was determined prospectively per Common Terminology Criteria for Adverse Events 3.0 standard. Presence of any one sensitive genotype (tissue plasminogen activator CC type, or angiotensin-converting enzyme D type (DD or DI) or TGFβ1 509CC type) is associated with a significantly higher mean grade of combined RITT. Error bars show the standard error of mean. There seems no significant difference in the overall score of RITT in patients with 1, 2, or all 3 high-risk variants. TGFβ1, transforming growth factor–beta1; RITT, combined radiation-induced thoracic toxicity. Journal of Thoracic Oncology 2013 8, 208-213DOI: (10.1097/JTO.0b013e318274592e) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions